Who is sponsoring NCT03492047?

NCT03492047 is sponsored by Ain Shams University.

What drugs are being tested in NCT03492047?

Interventions in NCT03492047: low dose N-acetylcysteine, high dose N-acetylcysteine, Paclitaxel.

What condition does NCT03492047 study?

NCT03492047 studies Peripheral Neuropathy Due to Chemotherapy.

Is NCT03492047 still recruiting?

NCT03492047 is currently completed. Last updated 27 February 2020.

Last reviewed 2020-02-27 · How we verify

NCT03492047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients

Completed Phase 1, PHASE2 Last updated 27 February 2020

What this trial tests

Phase 1, PHASE2 trial testing low dose N-acetylcysteine in Peripheral Neuropathy Due to Chemotherapy in 75 participants. Completed in 30 June 2019.

Timeline

1 April 2018

Primary endpoint
1 April 2019

30 June 2019

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	1 April 2018
Primary completion	1 April 2019
Estimated completion	30 June 2019
Sites	1 location across Egypt

Drugs / interventions tested

low dose N-acetylcysteine
high dose N-acetylcysteine
Paclitaxel — full drug profile →

Conditions studied

Peripheral Neuropathy Due to Chemotherapy — all drugs for Peripheral Neuropathy Due to Chemotherapy →

Sponsor

Ain Shams University

Who can join

Adults 18 to 85, any sex, with Peripheral Neuropathy Due to Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the effect of N-acetyl cysteine in combination with paclitaxel on the clinical outcomes of patients with peripheral neuropathy, paclitaxel-induced peripheral neuropathy affect quality of life in cancer patients. new therapeutic approches such as the antioxidant N-acetyl cysteine, showed to has neuroprotective effect, the aim of the study is to evaluate the effect of N- acetylcysteine(NAC) administration in the prevention of paclitaxel-Induced peripheral neuropathy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Metabolic Regulation of Redox Balance in Cancer.
Purohit V, Simeone DM, Lyssiotis CA. · · 2019 · cited 79× · PMID 31288436 · DOI 10.3390/cancers11070955
Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
Griñan-Lison C, Blaya-Cánovas JL, López-Tejada A, Ávalos-Moreno M, et al · · 2021 · cited 43× · PMID 33572626 · DOI 10.3390/antiox10020205
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG, Shawki MA, Aboelhassan R, El Wakeel LM. · · 2020 · cited 33× · PMID 32601973 · DOI 10.1007/s10549-020-05762-8
Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy.
Tsai CH, Lin YH, Li YS, Ho TL, et al · · 2021 · cited 12× · PMID 34502166 · DOI 10.3390/ijms22179257

Verify or expand the search:

Other recruiting trials for Peripheral Neuropathy Due to Chemotherapy

Currently open trials in the same condition.

NCT07423390 — Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy · Phase 3 · recruiting
NCT06807294 — Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT) · NA · recruiting
NCT06744816 — Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Sin · EARLY_PHASE1 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT06616649 — Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study. · NA · recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03492047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 27 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03492047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing